Nelfinavir is a clinically useful anti-HIV agent acting via inhibition of HIV-1 protease ($K_i=2 \text{ nM}$). It also displays efficacy in cancer, malaria, tuberculosis and SARS. Displays broad spectrum anticancer activity and induces endoplasmic reticulum stress, autophagy and apoptosis in vitro and in vivo. Inhibits the growth of HER2-positive breast cancer cells via inhibition of HSP90 through a novel mechanism.

1) Olmo et al. (2006), A review of nelfinavir for the treatment of HIV infection; Expert Opin. Drug Metab. Toxicol., 2, 285
2) Bruning et al. (2010), New prospects for nelfinavir in non-HIV-related diseases; Curr. Mol. Pharmacol., 3, 91
3) Gills et al. (2007), Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo; Clin. Cancer Res, 13, 5183

**Molecular Weight:** 663.88
**Molecular Formula:** $C_{32}H_{45}N_3O_4S \cdot CH_3SO_3H$
**Purity:** 98% by HPLC
**NMR:** (Conforms)
**Solubility:** DMSO (up to 70 mg/ml)
**Physical Description:** White solid
**Storage and Stability:** Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462
www.focusbiomolecules.com